Form 4: Cumberland Pharmaceuticals CFO John Hamm Reports Stock Transactions
SEC Form 4
Cumberland Pharmaceuticals' VP and CFO, John Hamm, reports the disposition of shares to cover tax obligations and the acquisition of options.
Summary
- On March 23, 2024, John Hamm, VP and CFO of Cumberland Pharmaceuticals, disposed of 445 shares of common stock at a price of $1.81 per share to cover tax obligations.
- Following this transaction, Hamm directly owns 26,003 shares of Cumberland Pharmaceuticals common stock.
- On March 25, 2024, Hamm acquired 5,500 options with an exercise price of $1.71, expiring on March 25, 2034.
- After this transaction, Hamm directly owns 12,500 options.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 03/23/2024 | John Hamm disposed of 445 shares of common stock at $1.81 per share. |
| 03/25/2024 | John Hamm acquired 5,500 options with an exercise price of $1.71, expiring on March 25, 2034. |
| 03/26/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.